The administration of many cancer drugs is tailored to genetic tests. Some genomic events,
eg, alterations of EGFR or BRAF oncogenes, result in the conformational change of the …

Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor,
have been identified in several neoplastic diseases. Rearranged ALK is a driver of …

Context Comprehensive genomic analysis of thyroid nodules for multiple classes of
molecular alterations detected in a large series of fine needle aspiration (FNA) samples has …

Background: BRAFV600E and N/H/K RAS mutations and oncogenic kinase fusions
involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase …

The past decade has brought significant advances in our understanding of the molecular
mechanisms of thyroid carcinogenesis. Among thyroid carcinomas, the most successful …

Background: Thyroid cancer is a common malignancy whose detection has increased
significantly in past decades. Most of the increased incidence is due to detection of early …

Thyroid carcinomas comprise distinct pathologic subtypes. However, advancements in
characterizing the molecular tumorigenesis of thyroid cancers have changed the treatment …

Background: Radioiodine (RAI) is commonly used for thyroid cancer treatment, although its
therapeutic benefits are restricted to iodine-avid tumors. The RAI-refractory disease …

This review aims to provide an overview of the molecular pathogenesis thyroid carcinomas,
emphasizing genetic alterations that are therapeutically actionable. The main pathways in …

In molecular pathology, predictive biomarkers identify which patients are likely to respond to
targeted drugs. These therapeutic agents block specific molecules directly involved in …